Boston Scientific Co. (NYSE:BSX) is Integral Health Asset Management LLC’s 4th Largest Position

Integral Health Asset Management LLC raised its stake in shares of Boston Scientific Co. (NYSE:BSX) by 8.3% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 650,000 shares of the medical equipment provider’s stock after acquiring an additional 50,000 shares during the period. Boston Scientific comprises about 4.8% of Integral Health Asset Management LLC’s investment portfolio, making the stock its 4th biggest position. Integral Health Asset Management LLC’s holdings in Boston Scientific were worth $50,056,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of BSX. Precision Wealth Strategies LLC acquired a new stake in shares of Boston Scientific during the 4th quarter valued at about $956,000. Aveo Capital Partners LLC grew its position in shares of Boston Scientific by 1.3% during the 4th quarter. Aveo Capital Partners LLC now owns 12,841 shares of the medical equipment provider’s stock valued at $742,000 after acquiring an additional 171 shares during the period. TrinityPoint Wealth LLC grew its position in shares of Boston Scientific by 5.9% during the 4th quarter. TrinityPoint Wealth LLC now owns 12,546 shares of the medical equipment provider’s stock valued at $725,000 after acquiring an additional 697 shares during the period. Clearbridge Investments LLC grew its position in shares of Boston Scientific by 14.0% during the 4th quarter. Clearbridge Investments LLC now owns 6,237 shares of the medical equipment provider’s stock valued at $361,000 after acquiring an additional 767 shares during the period. Finally, D.A. Davidson & CO. grew its position in shares of Boston Scientific by 6.0% during the 4th quarter. D.A. Davidson & CO. now owns 9,380 shares of the medical equipment provider’s stock valued at $542,000 after acquiring an additional 529 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on BSX shares. Morgan Stanley raised their target price on Boston Scientific from $79.00 to $92.00 and gave the company an “overweight” rating in a research report on Monday, July 15th. Needham & Company LLC lifted their price objective on Boston Scientific from $82.00 to $86.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. JPMorgan Chase & Co. lifted their price objective on Boston Scientific from $82.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, July 25th. Canaccord Genuity Group lifted their price objective on Boston Scientific from $83.00 to $88.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Finally, Truist Financial lifted their price objective on Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Three investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $86.65.

Boston Scientific Stock Up 0.3 %

BSX stock opened at $83.92 on Monday. The firm has a market cap of $123.12 billion, a PE ratio of 70.52, a PEG ratio of 2.75 and a beta of 0.79. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. The firm’s 50 day moving average price is $78.72 and its 200-day moving average price is $74.73. Boston Scientific Co. has a one year low of $48.35 and a one year high of $84.89.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, beating the consensus estimate of $0.58 by $0.04. The firm had revenue of $4.12 billion for the quarter, compared to analyst estimates of $4.02 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The business’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.53 EPS. On average, equities research analysts anticipate that Boston Scientific Co. will post 2.4 EPS for the current year.

Insider Activity

In other news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $74.12, for a total transaction of $517,579.96. Following the sale, the executive vice president now owns 40,188 shares of the company’s stock, valued at approximately $2,978,734.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 20,949 shares of company stock valued at $1,627,877. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.